UiPath Inc
NYSE:PATH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
UiPath Inc
NYSE:PATH
|
US |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
US |
|
Nurexone Biologic Inc
F:J90
|
CA |
|
N
|
Novartis AG
XMUN:NOT
|
CH |
|
E
|
Espey MFG and Electronics Corp
AMEX:ESP
|
US |
|
I
|
Intesa Sanpaolo SpA
DUS:IES
|
IT |
|
Pros Holdings Inc
NYSE:PRO
|
US |
|
Samsung Electronics Co Ltd
F:SSUN
|
KR |
|
C
|
Costco Wholesale Corp
XMUN:CTO
|
US |
|
Pierre et Vacances SA
PAR:VAC
|
FR |
|
A
|
Absolute Clean Energy PCL
SET:ACE
|
TH |
|
P
|
Prima Marine PCL
SET:PRM
|
TH |
Wall St Price Targets
PATH Price Targets Summary
UiPath Inc
According to Wall Street analysts, the average 1-year price target for PATH is 13.89 USD with a low forecast of 11.09 USD and a high forecast of 17.85 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PATH's stock price target?
Price Target
13.89
USD
According to Wall Street analysts, the average 1-year price target for PATH is 13.89 USD with a low forecast of 11.09 USD and a high forecast of 17.85 USD.
What is the Revenue forecast for UiPath Inc?
Projected CAGR
9%
Over the last 6 years, the compound annual growth rate for Revenue has been 30%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for UiPath Inc?
Projected CAGR
107%
The compound annual growth rate for Operating Income over the next 3 years is 107%.
What is the Net Income forecast for UiPath Inc?
Projected CAGR
24%
The compound annual growth rate for Net Income over the next 3 years is 24%.
